Catherine Weiss, PhD

Catherine Weiss, PhD is affiliated with Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, New Jersey. Dr Weiss is now retired. Catherine Weiss has authored or co-authored 3 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2019 and 2023. Their work focuses on Weight and Schizophrenia/Schizoaffective Disorders.

Weight Schizophrenia/Schizoaffective Disorders

Frequent co-authors

Stine R. Meehan John W. Newcomer Christoph U. Correll Dalei Chen Erin MacKenzie François Therrien Hans Eriksson Malaak Brubaker
JCP
Brexpiprazole in Patients With MDD and Prediabetes
Original Research

August 28, 2023

Some atypical antipsychotics, while efficacious as adjunctive treatments in major depressive disorder (MDD), can lead to adverse effects and weight gain. Adjunctive brexpiprazole had a limited impact on metabolic...
, , , et al
JCP
Effects of Brexpiprazole on Functioning in Schizophrenia
Original Research

March 1, 2022

Drawing on 4 RCTs and 2 open-label extension studies of brexpiprazole, this analysis looks at the effects of this medication on functioning both in the short term and over...
, , , et al
JCP
Original Research

October 1, 2019

Adjunctive atypical antipsychotics can increase antidepressant response in depressed patients, but may cause adverse metabolic effects. This study examines the metabolic effects of adjunctive brexpiprazole in patients with major...
, , , et al

Live Webinar
and Q&A With
Dr Deligiannidis

JULY 16 · REGISTER NOW
Webinar ad featuring Dr. Kristina M. Deligiannidis on PPD treatment options

Subscribe to read
more articles

Subscribe